Non-Coding RNAs as Biomarkers and Therapeutic Targets for Diabetic Kidney Disease

Yue-Yu Gu,Fu-Hua Lu,Xiao-Ru Huang,Lei Zhang,Wei Mao,Xue-Qing Yu,Xu-Sheng Liu,Hui-Yao Lan
DOI: https://doi.org/10.3389/fphar.2020.583528
IF: 5.6
2021-01-26
Frontiers in Pharmacology
Abstract:Diabetic kidney disease (DKD) is the most common diabetic complication and is a leading cause of end-stage kidney disease. Increasing evidence shows that DKD is regulated not only by many classical signaling pathways but also by epigenetic mechanisms involving chromatin histone modifications, DNA methylation, and non-coding RNA (ncRNAs). In this review, we focus on our current understanding of the role and mechanisms of ncRNAs, including microRNAs (miRNAs) and long non-coding RNAs (lncRNAs) in the pathogenesis of DKD. Of them, the regulatory role of TGF-β/Smad3-dependent miRNAs and lncRNAs in DKD is highlighted. Importantly, miRNAs and lncRNAs as biomarkers and therapeutic targets for DKD are also described, and the perspective of ncRNAs as a novel therapeutic approach for combating diabetic nephropathy is also discussed.
pharmacology & pharmacy
What problem does this paper attempt to address?